Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network
Autore:
Hainsworth, JD; Burris, HA; Calvert, SW; Willcutt, NT; Scullin, DC; Bramham, J; Greco, FA;
Indirizzi:
Sarah Cannon Canc Ctr, Centennial Med Ctr, Nashville, TN 37203 USA Sarah Cannon Canc Ctr Nashville TN USA 37203 Ctr, Nashville, TN 37203 USA Graves Gilbert Clin, Bowling Green, KY USA Graves Gilbert Clin Bowling Green KY USA ert Clin, Bowling Green, KY USA
Titolo Testata:
CANCER INVESTIGATION
fascicolo: 4, volume: 19, anno: 2001,
pagine: 335 - 339
SICI:
0735-7907(2001)19:4<335:GITSTO>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMBINATION-CHEMOTHERAPY; METASTATIC CARCINOMA; RANDOMIZED TRIAL; 5-FLUOROURACIL; DOXORUBICIN; CISPLATIN; MITOMYCIN; ETOPOSIDE;
Keywords:
carcinoma of unknown primary site; gemcitabine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Hainsworth, JD Sarah Cannon Canc Ctr, Centennial Med Ctr, 250 25th Ave N,Suite 412, Nashville, TN 37203 USA Sarah Cannon Canc Ctr 250 25th Ave N,Suite 412 Nashville TN USA 37203
Citazione:
J.D. Hainsworth et al., "Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network", CANCER INV, 19(4), 2001, pp. 335-339

Abstract

The purpose of this study was to evaluate the activity of single-agent gemcitabine in previously treated patients with carcinoma of unknown primary site. Between January 1997 and October 1998, 39 patients were enrolled in this multicenter Phase II trial performed in the Minnie Pearl Cancer Researchnetwork. Twenty-seven patients (69%) had adenocarcinoma or poorly differentiated adenocarcinoma; 35 patients (90%) had previously received treatment with chemotherapy regiments containing both a platinum agent and a taxane. Only 21% of patients had ever responded to previous therapy. Gemcitabine 1000 mg/m(2) was administered intravenously on days 1, 8, and 15 of each 28-day course. Three of 36 evaluable patients (8%) had partial responses, and 9patients (25%) had minor responses or stable disease with improved symptoms. The median time to progression for patients with partial responses or stable disease/improved symptoms was 5 months. Treatment was well tolerated, with uncommon grade 3 or 4 toxicity. Gemcitabine produced a low objective rate in this refractory patient population, although approximately one-thirdof patients experienced symptomatic improvement. Treatment with gemcitabine was well tolerated. Because gemcitabine has activity against a variety ofadenocarcinomas, further evaluation of this agent as part of first-line therapy for patients with carcinoma of unknown primary site is appropriate.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 19:56:38